Table 1.
Comparison between characteristics of patients with NPC treated using IMPT and VMAT.
| Characteristics | IMPT (n = 80) | VMAT (n = 80) | p-Value |
|---|---|---|---|
| Age at diagnosis, mean (IQR), y | 47.6 (22.6–79.2) | 50.1 (27.3–79.2) | |
| Age, n (%) | 0.844 | ||
| >60 y/o | 65 (81.3) | 63 (78.8) | |
| <60 y/o | 15(18.7) | 17 (21.2) | |
| Sex, n (%) | 0.284 | ||
| Male | 64 (80) | 70 (87.5) | |
| Female | 16 (20) | 10 (12.5) | |
| Charlson Comorbidity Index | 0.298 | ||
| 0–1 | 69 (86.3) | 63 (78.8) | |
| ≥2 | 11 (13.8) | 17 (21.3) | |
| WHO type, n (%) | 0.845 | ||
| I | 1 (1.3) | 1 (1.3) | |
| II | 24 (30.0) | 21 (26.3) | |
| III | 55 (68.8) | 58 (72.5) | |
| T-stage, n (%) | 0.760 | ||
| T1 | 32 (40.0) | 25 (43.8) | |
| T2 | 11 (13.8) | 8 (12.5) | |
| T3 | 19 (23.8) | 7 (17.5) | |
| T4 | 18 (22.5) | 14 (26.3) | |
| N-stage, n (%) | 0.909 | ||
| N0 | 13 (16.3) | 10 (20.0) | |
| N1 | 39 (48.8) | 34 (46.3) | |
| N2 | 15 (18.8) | 12 (16.3) | |
| N3 | 13 (16.3) | 18 (17.5) | |
| AJCC 8th stage, n (%) | 0.945 | ||
| I | 8 (10.0) | 9 (11.3) | |
| II | 21 (26.3) | 21 (26.3) | |
| III | 19 (23.8) | 16 (20.0) | |
| IV | 32 (40.0) | 34 (42.6) | |
| EBV PCR titer, n (%) | 0.257 | ||
| >200 | 45 (56.3) | 52 (65.0) | |
| <200 | 35 (43.8) | 28 (35.0) | |
| Treatment modality, n (%) | 1.000 | ||
| Chemo with CCRT | 10 (12.5) | 10 (12.5) | |
| CCRT | 59 (73.8) | 59 (73.8) | |
| RT alone | 11(13.7) | 11(13.7) | |
| Induction chemotherapy | 0.531 | ||
| GP | 9 (90.0) | 8 (80.0) | |
| TP | 1 (10.0) | 2 (20.0) | |
| Concurrent chemotherapy regimen | 0.459 | ||
| PUL | 58 (84.1) | 61 (88.4) | |
| Weekly cisplatin | 11 (15.9) | 8 (11.6) | |
| Cisplatin total dose (mg/m2) | 0.111 | ||
| <200 | 5 (7.2) | 11 (15.9) | |
| ≥200 | 64 (92.8) | 58 (84.1) | |
| Smoking at diagnosis, n (%) | 0.817 | ||
| No | 43 (54.4) | 45 (56.3) | |
| Yes | 36 (45.6) | 35 (43.8) |
Abbreviations: IMPT—Intensity-modulated proton therapy, VMAT—Volumetric modulated arc therapy, IQR—Interquartile range, EBV—Epstein–Barr virus, CCRT—Concurrent chemoradiotherapy, WHO—World Health Organization, AJCC—American Joint Committee on Cancer, PCR—Polymerase chain reaction, PUL—Cisplatin (P) and tegafur plus uracil (U) plus leucovorin, GP—Gemcitabine and cisplatin, TP—Docetaxel and cisplatin.